Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Annabrita Hemmes"'
Autor:
Sarang S. Talwelkar, Mikko I. Mäyränpää, Julia Schüler, Nora Linnavirta, Annabrita Hemmes, Simone Adinolfi, Matti Kankainen, Wolfgang Sommergruber, Anna‐Liisa Levonen, Jari Räsänen, Aija Knuuttila, Emmy W. Verschuren, Krister Wennerberg
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 747-764 (2023)
Treatment with anaplastic lymphoma kinase (ALK) inhibitors significantly improves outcome for non‐small‐cell lung cancer (NSCLC) patients with ALK‐rearranged tumors. However, clinical resistance typically develops over time and, in the majority
Externí odkaz:
https://doaj.org/article/1563d14766b740a0a1ffecc8176e6bc3
Autor:
James H. A. Clubb, Tatiana V. Kudling, Mykhailo Girych, Lyna Haybout, Santeri Pakola, Firas Hamdan, Víctor Cervera-Carrascon, Annabrita Hemmes, Susanna Grönberg-Vähä-Koskela, João Manuel Santos, Dafne C. A. Quixabeira, Saru Basnet, Camilla Heiniö, Victor Arias, Elise Jirovec, Shreyas Kaptan, Riikka Havunen, Suvi Sorsa, Abdullah Erikat, Joel Schwartz, Marjukka Anttila, Katri Aro, Tapani Viitala, Ilpo Vattulainen, Vincenzo Cerullo, Anna Kanerva, Akseli Hemminki
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, but preclinical testing of hypotheses such as combination therapies has been complicated, in part due to species incompatibility issues. For example, one of
Externí odkaz:
https://doaj.org/article/72872e048c8c48dd8faf69a636eddea5
Autor:
Iris A. K. Lähdeniemi, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar, Jie Bao, Nora Linnavirta, Ceren Şeref Vujaklija, Elina A. Kiss, Annabrita Hemmes, Emmy W. Verschuren
Publikováno v:
Biology Open, Vol 11, Iss 12 (2022)
Externí odkaz:
https://doaj.org/article/c0f7ba253ae148818c5beb30806d7339
Autor:
Sarang S. Talwelkar, Iris A.K. Lähdeniemi, Mikko I. Mäyränpää, Annabrita Hemmes, Nora Linnavirta, Jari Räsänen, Aija Knuuttila, Krister Wennerberg, Emmy W. Verschuren
Publikováno v:
STAR Protocols, Vol 3, Iss 4, Pp 101720- (2022)
Summary: Drug sensitivity data acquired from solid tumor-derived cultures are often unsuitable for personalized treatment guidance due to the lengthy turnaround time. Here, we present a protocol for determining ex vivo drug sensitivities using fresh
Externí odkaz:
https://doaj.org/article/006c6459adf0456781a8ab0e155bc7a4
Autor:
Ashwini S. Nagaraj, Jenni Lahtela, Annabrita Hemmes, Teijo Pellinen, Sami Blom, Jennifer R. Devlin, Kaisa Salmenkivi, Olli Kallioniemi, Mikko I. Mäyränpää, Katja Närhi, Emmy W. Verschuren
Publikováno v:
Cell Reports, Vol 18, Iss 3, Pp 673-684 (2017)
Lung cancers exhibit pronounced functional heterogeneity, confounding precision medicine. We studied how the cell of origin contributes to phenotypic heterogeneity following conditional expression of KrasG12D and loss of Lkb1 (Kras;Lkb1). Using proge
Externí odkaz:
https://doaj.org/article/4865c03d589649f090200e998d1e2cd4
Autor:
Jenni Lahtela, Barun Pradhan, Katja Närhi, Annabrita Hemmes, Merja Särkioja, Panu E. Kovanen, Arthur Brown, Emmy W. Verschuren
Publikováno v:
Disease Models & Mechanisms, Vol 8, Iss 4, Pp 393-401 (2015)
Treatment of non-small cell lung cancer (NSCLC) is based on histological analysis and molecular profiling of targetable driver oncogenes. Therapeutic responses are further defined by the landscape of passenger mutations, or loss of tumor suppressor g
Externí odkaz:
https://doaj.org/article/c9104109995c4c7a90ef3d63bcfdad41
Autor:
Tuomas Mirtti, Antti Rannikko, Olli Kallioniemi, Stig Nordling, Anu Kenttämies, Juho Eineluoto, Katja Välimäki, Annabrita Hemmes, Riku Turkki, Sami Blom, Kevin Sandeman, Teijo Pellinen
Some clinically significant prostate cancers are missed by MRI. We asked whether the tumor stroma in surgically treated localized prostate cancer lesions positive or negative with MRI are different in their cellular and molecular properties, and whet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b80a95e40ca19584e84700f27fafab86
https://doi.org/10.1158/2767-9764.c.6550682
https://doi.org/10.1158/2767-9764.c.6550682
Autor:
Tuomas Mirtti, Antti Rannikko, Olli Kallioniemi, Stig Nordling, Anu Kenttämies, Juho Eineluoto, Katja Välimäki, Annabrita Hemmes, Riku Turkki, Sami Blom, Kevin Sandeman, Teijo Pellinen
Supplementary Tables S1-S7. Supplementary Figures S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aeee45363f24aa0999c1dc8acd78302
https://doi.org/10.1158/2767-9764.22544537
https://doi.org/10.1158/2767-9764.22544537
Autor:
Emmy W. Verschuren, Krister Wennerberg, Mikko I. Mäyränpää, Kaisa Salmenkivi, Pipsa Saharinen, Elina A. Kiss, Swapnil Potdar, Annabrita Hemmes, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar
Supplementary text and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25da8709577071f02aaeaf9cd8b88369
https://doi.org/10.1158/1535-7163.22509210.v1
https://doi.org/10.1158/1535-7163.22509210.v1
Autor:
Emmy W. Verschuren, Krister Wennerberg, Mikko I. Mäyränpää, Kaisa Salmenkivi, Pipsa Saharinen, Elina A. Kiss, Swapnil Potdar, Annabrita Hemmes, Jennifer R. Devlin, Ashwini S. Nagaraj, Sarang S. Talwelkar
Most non–small cell lung cancers (NSCLC) contain nontargetable mutations, including KRAS, TP53, or STK11/LKB1 alterations. By coupling ex vivo drug sensitivity profiling with in vivo drug response studies, we aimed to identify drug vulnerabilities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d26d521c92c9d7c4073c63d907f5285
https://doi.org/10.1158/1535-7163.c.6539226.v1
https://doi.org/10.1158/1535-7163.c.6539226.v1